Recent studies assigning a dominant gatekeeper role for TGFβ3 in malignant glioblastoma progression [5], as well as specifically implicating TGFβ1 in breast and gastric cancers [6,7], support the continued pre-clinical and clinical investigation of these novel TGFβ antibodies. Here, TGFB3 is linked to glioblastoma.